Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose.
Remberger
M
M
Mattsson
J
J
Svahn
B-M
BM
Ringdén
O
O
D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000276:immunology*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006680:HLA Antigens / Q000276:immunology*; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007938:Leukemia / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D035781:Siblings; D033581:Stem Cell Transplantation; D019172:Transplantation Conditioning / Q000379:methods*; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D000970:Antineoplastic Agents; D006680:HLA Antigens; D014740:Vidarabine; C024352:fludarabine